A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Liu, Zhida ^a,b,c   Zhou, Hang ^a,b   Wang, Wenjun ^a,b   Fu, Yang Xin ^c   Zhu, Mingzhao ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Cervical cancer; DEC205; dendritic cell; HPV E7; PD 1; PD L1; therapeutic vaccine

Indexed keywords

ANTIBODY; DENDRITIC CELL VACCINE; HUMAN PAPILLOMA VIRUS ONCOGENE E7 SYNTHETIC VACCINE; HYBRID PROTEIN; PD L1 ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; NONHUMAN; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; STAINING; TUMOR GROWTH; TUMOR IMMUNITY; UTERINE CERVIX CANCER;

EID: 84969651505     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1147641     Document Type: Article

References (52)

1. J.M.Walboomers, M.V.Jacobs, M.M.Manos, F.X.Bosch, J.A.Kummer, K.V.Shah, P.J.Snijders, J.Peto, C.J.Meijer, N.Muñoz. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9; PMID:10451482; 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
2. M.Steben, E.Duarte-Franco. Human papillomavirus infection: epidemiology and pathophysiology. Gynecologic Oncol 2007; 107:S2-5; PMID:17938014; 10.1016/j.ygyno.2007.07.067
3. C.A.Moody, L.A.Laimins. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10:550-60; PMID:20592731; 10.1038/nrc2886
4. P.Sharma, J.P.Allison. The future of immune checkpoint therapy. Science (New York, NY) 2015; 348:56-61; PMID:25838373; 10.1126/science.aaa8172
5. C.Badoual, S.Hans, N.Merillon, C.Van Ryswick, P.Ravel, N.Benhamouda, E.Levionnois, M.Nizard, A.Si-Mohamed, N.Besnier et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; 10.1158/0008-5472.CAN-12-2606
6. S.J.Piersma. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Micro Environment 2011; 4:361-75; PMID:21626415; 10.1007/s12307-011-0066-7
7. S.Patel, S.Chiplunkar. Host immune responses to cervical cancer. Curr Opin Obstetrics Gynecol 2009; 21:54-9; PMID:19125004; 10.1097/GCO.0b013e32831a9890
8. H.L.Wang, H.Xu, W.H.Lu, L.Zhu, Y.H.Yu, F.Z.Hong. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer. Arch Gynecol Obstetrics 2014; 289:155-62; PMID:23912529; 10.1007/s00404-013-2938-1
9. A.D.Santin, S.Bellone, M.Palmieri, A.Zanolini, A.Ravaggi, E.R.Siegel, J.J.Roman, S.Pecorelli, M.J.Cannon. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 2008; 82:1968-79; PMID:18057249; 10.1128/JVI.02343-07
10. S.Bellone, S.Pecorelli, M.J.Cannon, A.D.Santin. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anti Cancer Therapy 2007; 7:1473-86; PMID:17944571; 10.1586/14737140.7.10.1473
11. A.D.Santin, S.Bellone, M.Palmieri, A.Ravaggi, C.Romani, R.Tassi, J.J.Roman, A.Burnett, S.Pecorelli, M.J.Cannon. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecologic Oncol 2006; 100:469-78; PMID:16249018; 10.1016/j.ygyno.2005.09.040
12. G.J.Adema, I.J.de Vries, C.J.Punt, C.G.Figdor. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 2005; 17:170-4; PMID:15766677; 10.1016/j.coi.2005.01.004
13. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; 10.1016/j.immuni.2013.07.004
14. W.Kastenmuller, K.Kastenmuller, C.Kurts, R.A.Seder. Dendritic cell-targeted vaccines-hope or hype? Nat Rev Immunol 2014; 14:705-11; PMID:25190285; 10.1038/nri3727
15. P.Guermonprez, N.Khelef, E.Blouin, P.Rieu, P.Ricciardi-Castagnoli, N.Guiso, D.Ladant, C.Leclerc. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the α(M)β(2) integrin (CD11b/CD18). J Exp Med 2001; 193:1035-44; PMID:11342588; 10.1084/jem.193.9.1035
16. G.Moron, G.Dadaglio, C.Leclerc. New tools for antigen delivery to the MHC class I pathway. Trends Immunol 2004; 25:92-7; PMID:15102368; 10.1016/j.it.2003.11.008
17. P.Berraondo, C.Nouze, X.Preville, D.Ladant, C.Leclerc. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67:8847-55; PMID:17875726; 10.1158/0008-5472.CAN-07-0321
18. X.Preville, D.Ladant, B.Timmerman, C.Leclerc. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005; 65:641-9; PMID:15695409
19. M.V.Dhodapkar, M.Sznol, B.Zhao, D.Wang, R.D.Carvajal, M.L.Keohan, E.Chuang, R.E.Sanborn, J.Lutzky, J.Powderly et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Translational Med 2014; 6:232ra51; PMID:24739759; 10.1126/scitranslmed.3008068
20. L.K.Swee, C.P.Guimaraes, S.Sehrawat, E.Spooner, M.I.Barrasa, H.L.Ploegh. Sortase-mediated modification of alphaDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes. Proc Natl Acad Sci USA 2013; 110:1428-33; PMID:23297227; 10.1073/pnas.1214994110
21. B.J.Flynn, K.Kastenmuller, U.Wille-Reece, G.D.Tomaras, M.Alam, R.W.Lindsay, A.M.Salazar, B.Perdiguero, C.E.Gomez, R.Wagner et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 2011; 108:7131-6; PMID:21467219; 10.1073/pnas.1103869108
22. C.Cheong, J.H.Choi, L.Vitale, L.Z.He, C.Trumpfheller, L.Bozzacco, Y.Do, G.Nchinda, S.H.Park, D.B.Dandamudi et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010; 116:3828-38; PMID:20668230; 10.1182/blood-2010-06-288068
23. L.C.Bonifaz, D.P.Bonnyay, A.Charalambous, D.I.Darguste, S.Fujii, H.Soares, M.K.Brimnes, B.Moltedo, T.M.Moran, R.M.Steinman. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; 10.1084/jem.20032220
24. G.Nchinda, J.Kuroiwa, M.Oks, C.Trumpfheller, C.G.Park, Y.Huang, D.Hannaman, S.J.Schlesinger, O.Mizenina, M.C.Nussenzweig et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 2008; 118:1427-36; PMID:18324335; 10.1172/JCI34224
25. T.S.Johnson, K.Mahnke, V.Storn, K.Schonfeld, S.Ring, D.M.Nettelbeck, H.J.Haisma, F.Le Gall, R.E.Kontermann, A.H.Enk. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin Cancer Res 2008; 14:8169-77; PMID:19088032; 10.1158/1078-0432.CCR-08-1474
26. Z.Liu, H.Zhou, W.Wang, W.Tan, Y.X.Fu, M.Zhu. A novel method for synthetic vaccine construction based on protein assembly. Scientific Reports 2014; 4:7266; PMID:25434527; 10.1038/srep07266
27. L.Bonifaz, D.Bonnyay, K.Mahnke, M.Rivera, M.C.Nussenzweig, R.M.Steinman. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:12486105; 10.1084/jem.20021598
28. A.O.Kamphorst, P.Guermonprez, D.Dudziak, M.C.Nussenzweig. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J Immunol (Baltimore, Md: 1950) 2010; 185:3426-35; PMID:20729332; 10.4049/jimmunol.1001205
29. C.F.Hung, B.Ma, A.Monie, S.W.Tsen, T.C.Wu. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Exp Opin Biol Therapy 2008; 8:421-39; PMID:18352847; 10.1517/14712598.8.4.421
30. C.L.Trimble, M.P.Morrow, K.A.Kraynyak, X.Shen, M.Dallas, J.Yan, L.Edwards, R.L.Parker, L.Denny, M.Giffear et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet (London, England) 2015; 386:2078-88; PMID:26386540; 10.1016/S0140-6736(15)00239-1
31. L.Delamarre, I.Mellman, M.Yadav. Cancer immunotherapy. Neo approaches to cancer vaccines. Science (New York, NY) 2015; 348:760-1; PMID:25977539; 10.1126/science.aab3465
32. T.N.Schumacher, R.D.Schreiber. Neoantigens in cancer immunotherapy. Science (New York, NY) 2015; 348:69-74; PMID:25838375; 10.1126/science.aaa4971
33. S.Rogers, R.Wells, M.Rechsteiner. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science (New York, NY) 1986; 234:364-8; PMID:2876518; 10.1126/science.2876518
34. A.L.Decatur, D.A.Portnoy. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science (New York, NY) 2000; 290:992-5; PMID:11062133; 10.1126/science.290.5493.992
35. D.A.Sewell, V.Shahabi, G.R.Gunn, 3rd, Z.K.Pan, M.E.Dominiecki, Y.Paterson. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 2004; 64:8821-5; PMID:15604239; 10.1158/0008-5472.CAN-04-1958
36. J.Couzin-Frankel. Breakthrough of the year 2013. Cancer immunotherapy. Science (New York, NY) 2013; 342:1432-3; PMID:24357284; 10.1126/science.342.6165.1432
37. S.M.Ansell, A.M.Lesokhin, I.Borrello, A.Halwani, E.C.Scott, M.Gutierrez, S.J.Schuster, M.M.Millenson, D.Cattry, G.J.Freeman et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Eng J Med 2015; 372:311-9; PMID:25482239; 10.1056/NEJMoa1411087
38. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, W.J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; 10.1056/NEJMoa1200694
39. O.Hamid, R.D.Carvajal. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Exp Opin Biol Therapy 2013; 13:847-61; PMID:23421934; 10.1517/14712598.2013.770836
40. S.L.Topalian, C.G.Drake, D.M.Pardoll. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; 10.1016/j.coi.2011.12.009
41. J.D.Wolchok, H.Kluger, M.K.Callahan, M.A.Postow, N.A.Rizvi, A.M.Lesokhin, N.H.Segal, C.E.Ariyan, R.A.Gordon, K.Reed et al. Nivolumab plus ipilimumab in advanced melanoma. N Eng J Med 2013; 369:122-33; PMID:23724867; 10.1056/NEJMoa1302369
42. J.Fu, I.J.Malm, D.K.Kadayakkara, H.Levitsky, D.Pardoll, Y.J.Kim. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014; 74:4042-52; PMID:24812273; 10.1158/0008-5472.CAN-13-2685
43. B.Schreiner, M.Mitsdoerffer, B.C.Kieseier, L.Chen, H.P.Hartung, M.Weller, H.Wiendl. Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuro Immunol 2004; 155:172-82; PMID:15342209; 10.1016/j.jneuroim.2004.06.013
44. M.B.Fuertes, A.K.Kacha, J.Kline, S.R.Woo, D.M.Kranz, K.M.Murphy, T.F.Gajewski. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{α}+ dendritic cells. J Exp Med 2011; 208:2005-16; PMID:21930765; 10.1084/jem.20101159
45. M.S.Diamond, M.Kinder, H.Matsushita, M.Mashayekhi, G.P.Dunn, J.M.Archambault, H.Lee, C.D.Arthur, J.M.White, U.Kalinke et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208:1989-2003; PMID:21930769; 10.1084/jem.20101158
46. X.Yang, X.Zhang, M.L.Fu, R.R.Weichselbaum, T.F.Gajewski, Y.Guo, Y.X.Fu. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014; 25:37-48; PMID:24434209; 10.1016/j.ccr.2013.12.004
47. M.B.Fuertes, S.R.Woo, B.Burnett, Y.X.Fu, T.F.Gajewski. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013; 34:67-73; PMID:23122052; 10.1016/j.it.2012.10.004
48. M.Vanneman, G.Dranoff. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237-51; PMID:22437869; 10.1038/nrc3237
49. M.Mkrtichyan, N.Chong, R.Abu Eid, A.Wallecha, R.Singh, J.Rothman, S.N.Khleif. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer 2013; 1:15; PMID:24829751; 10.1186/2051-1426-1-15
50. B.Dai, L.Xiao, P.D.Bryson, J.Fang, P.Wang. PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines. Mol Ther 2012; 20:1800-9; PMID:22588271; 10.1038/mt.2012.98
51. R.S.Soong, L.Song, J.Trieu, J.Knoff, L.He, Y.C.Tsai, W.Huh, Y.N.Chang, W.F.Cheng, R.B.Roden et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNgamma. Clin Cancer Res 2014; 20:5456-67; PMID:24893628; 10.1158/1078-0432.CCR-14-0344
52. Q.Zeng, S.Peng, A.Monie, M.Yang, X.Pang, C.F.Hung, T.C.Wu. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Human Gene Therapy 2011; 22:809-19; PMID:21128743; 10.1089/hum.2010.071